Continuation of burosumab during pregnancy in a patient with X-linked hypophosphatemia
JCEM Case Reports · 27.07.2026 · 4 (9)
DOI: 10.1210/jcemcr/luag233 ↗Kurz gefasst
Fallbericht in der Zeitschrift JCEM Case Reports, online erschienen am 24.08.2026. Verfasst von Atsushi Suzuki und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Diabetes and Metabolism, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Burosumab is a well-established treatment for X-linked hypophosphatemia (XLH), but safety data during pregnancy are limited. We present the case of a woman in her 30s with XLH who continued to take burosumab during pregnancy to prevent symptomatic relapse. She gave birth to a male infant via cesarean section at 37 weeks without obstetric complications. The neonate exhibited a markedly elevated intact fibroblast growth factor 23 level {48 700 pg/mL (SI: 1933 pmol/L) (reference range, 19.9-52.9 pg/mL [SI: 0.79-2.10 pmol/L])} shortly after birth. This level declined rapidly to 151 pg/mL (SI: 4.7 pmol/L) by age 7 months but remained above the normal range. Genetic testing revealed a phosphate-regulating endopeptidase, X-linked gene mutation in both mother and child. The infant was initially managed with conventional therapy before transitioning to burosumab at 8 months of age. At the 1-year follow-up, the child demonstrated no apparent developmental delay or adverse skeletal events. This case presents real-world evidence of continued burosumab exposure during pregnancy in a woman with XLH. Although no apparent short-term maternal or fetal adverse events were observed, the safety of burosumab use during pregnancy is uncertain, and more clinical data, particularly with long-term follow-up, are needed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology, Diabetes and Metabolism, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan.
- Department of Obstetrics and Gynecology, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan.
- Department of Pediatrics, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan.
ORCID-Profile: Atsushi Suzuki
Zitieren
APA
Suzuki, A., Moriyama, Y., Mizuno, H., & Nishizawa, H. (2026). Continuation of burosumab during pregnancy in a patient with X-linked hypophosphatemia. JCEM Case Reports, 4(9). https://doi.org/10.1210/jcemcr/luag233
Vancouver
Suzuki A, Moriyama Y, Mizuno H, Nishizawa H. Continuation of burosumab during pregnancy in a patient with X-linked hypophosphatemia. JCEM Case Reports. 2026;4(9). doi:10.1210/jcemcr/luag233
BibTeX
@article{Suzuki2026,
author = {Suzuki, Atsushi and Moriyama, Yoshinori and Mizuno, Haruo and Nishizawa, Haruki},
title = {Continuation of burosumab during pregnancy in a patient with X-linked hypophosphatemia},
journal = {JCEM Case Reports},
year = {2026},
volume = {4},
number = {9},
doi = {10.1210/jcemcr/luag233}
}
EUVIMED